Skip to main content

Clinical trials support unit (CTSU)

The Clinical Trials Support Unit (CTSU) is an operational support unit for academic clinical research into all types of cancer. Certain scientific questions of interest to patients can only be understood by means of academic research. This academic research must comply with all quality standards and legal and regulatory requirements applicable to research. It must also be carried out efficiently.

It is for all these reasons that the Institut Bordet, in a desire to develop and encourage such research, decided to create the CTSU. This unit within the Institution brings together the skills and resources needed to conduct high-level research. The CTSU team is responsible for responding to research questions and evaluating the benefits and risks of drugs and procedures, while always ensuring that the patients participating in the clinical studies are adequately protected. 

https://ctsu.bordet.be

Our team

Director of Research Administration
Marielle Sautois

Head of CTSU Operations
Julie Gaye

Associate Head of CTSU Operations
Magalie Krieguer

Head of CTSU IT Support
David Lerens

Medical team 
Michail Ignatiadis, Academic Trials Promoting Team Leader
Evandro De Azambuja, Head of Medical Support Team

 Scientific publications

Fat density is a novel prognostic marker in patients with esophageal cancer.

Authors : Anciaux M, Van Gossum A, Wenglinski C, Ameye L, Guiot T, Flamen P, Demetter P, Deleporte A, Sclafani F, Donckier V, Hendlisz A, Vandeputte C
Year : 2020
Journal : Clin Nutr ESPEN
Volume : 39
Pages : 124-130

Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome.

Authors : Venet D, Fimereli D, Rothé F, Boeckx B, Maetens M, Majjaj S, Rouas G, Capra M, Bonizzi G, Contaldo F, Galant C, Piccart M, Pruneri G, Larsimont D, Lambrechts D, Desmedt C, Sotiriou C
Year : 2020
Journal : EBioMedicine
Volume : 56
Pages : 102793

Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.

Authors : Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, Vanderlinden B, Reynaert N, Hendlisz A, Lam M, Deroose CM, Ahmadzadehfar H, Flamen P
Year : 2019
Journal : Eur J Nucl Med Mol Imaging
Volume : 46
Pages : 2270-2279

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Authors : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 304

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Authors : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3581-3588